



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38

## Health Technology Wales

### Appraisal Process Guide

#### Contents

1. Purpose of this document.....	4
2. Introduction to HTW and our process.....	4
Figure 1. Appraisals process flow diagram .....	5
3: Who's involved and how.....	6
3.1 Participants in the process .....	6
3.1.1 HTW decision-making committees, advisory groups, and staff .....	6
3.1.1.1 HTW Staff .....	6
3.1.1.2 The Assessment Group .....	6
3.1.1.3 The PPISG.....	6
3.1.1.4 The Appraisal Panel .....	7
3.1.2 Stakeholders outside of HTW .....	7
3.1.2.1 Topic proposer .....	7
3.1.2.2 Industry representatives.....	7
3.1.2.3 Subject experts .....	8
3.1.2.4 PPI representatives .....	8
3.1.2.5 Wider stakeholders.....	8
3.2 How participants are involved.....	8
3.2.1 HTW decision-making committees, advisory boards, and staff.....	8
3.2.1.1 HTW Staff.....	8
3.2.1.2 The Assessment Group .....	9
3.2.1.3 The PPISG .....	9
3.2.1.4 The Appraisal Panel.....	10
3.2.2 Stakeholders outside of HTW .....	10
3.2.2.1 Topic proposer.....	10
3.2.2.2 Industry representatives .....	10
3.2.2.3 Subject experts .....	11
3.2.2.4 PPI representatives.....	11
3.2.2.5 Other stakeholders .....	11
3.3 Dols and confidentiality.....	11
Table 1. Process for handling relevant Dols .....	12
4. Initial topic submission and selection.....	12
4.1 HTW's remit.....	12
4.2 Sources of topics.....	13



39	4.2.1 Suggest a Topic form.....	13
40	4.2.2 NHS Innovation Service.....	13
41	4.2.3 Other sources of topics.....	13
42	4.3 Topic selection for further exploration.....	14
43	4.3.1 Topic eligibility for topic exploration.....	14
44	4.3.2 Reviewing topic submissions for eligibility and further appraisal.....	14
45	4.3.3 Topics not suitable for topic exploration.....	14
46	5. Production of a TER.....	15
47	5.1 TER contents.....	15
48	5.2 TER process.....	15
49	6. Topic selection and prioritisation for the appraisal work programme.....	17
50	6.1 Why is prioritisation important?.....	17
51	6.2 Prioritisation process.....	17
52	Table 2. Potential topic outcomes following Assessment Group discussion.....	18
53	7. Production of an EAR.....	19
54	7.1 Planning the appraisal.....	19
55	7.1.1 Topic protocol.....	20
56	7.1.1.1 Protocol contents.....	20
57	7.1.2 Economic plan.....	21
58	7.1.3 PPI mechanism.....	21
59	7.1.4 Timelines and project plans.....	22
60	7.1.5 Sign off.....	22
61	7.1.5.1 Protocol amendments.....	22
62	7.2 Evidence identification.....	22
63	7.2.1 Searching for the evidence (literature searching).....	23
64	7.2.1.1 Planning the search.....	23
65	7.2.1.2 Sources.....	23
66	7.2.1.4 Writing and running the search.....	23
67	7.2.1.5 Updating searches prior to publication.....	23
68	7.2.1.6 Documenting the search.....	24
69	7.2.2 Other sources.....	24
70	7.3 Selection, synthesis, and presentation of effectiveness evidence.....	24
71	7.3.1 Study selection.....	25
72	7.3.1.1 Types of evidence included.....	25
73	7.3.2 Data extraction.....	25
74	7.3.2.1 Assessment of certainty of the evidence.....	26
75	7.3.3 Synthesis.....	26
76	7.4 Economic evidence.....	26
77	7.4.1 Types of economic evaluation.....	27



78	7.4.1.1 Choice of comparator.....	27
79	7.4.1.2 Perspective of analysis.....	27
80	7.4.1.3 Time horizon.....	27
81	7.4.1.4 Discounting.....	28
82	7.4.2 Model inputs.....	28
83	7.4.2.1 Effectiveness.....	28
84	7.4.2.2 Quality of life.....	29
85	7.4.2.3 Resource use and costs.....	29
86	7.4.3 Interpreting results.....	30
87	7.4.4 Uncertainty and sensitivity analysis.....	30
88	7.4.4.1 Deterministic sensitivity analysis.....	30
89	7.4.4.2 Probabilistic sensitivity analysis.....	30
90	7.4.4.3 Scenario analysis.....	30
91	7.5 PPI.....	31
92	7.5.1 Engagement with patient and carer organisations.....	31
93	7.5.1.1 Patient and carer submissions.....	31
94	7.5.1.2 Direct patient evidence.....	32
95	7.5.2 PPI literature reviews.....	32
96	7.6 Additional considerations.....	33
97	7.7 Quality assurance, oversight, and external review.....	33
98	7.7.1 Quality assurance.....	33
99	7.7.2. Review by the HTW Assessment Group.....	34
100	7.7.3 External expert review.....	34
101	7.8 Finalising the EAR.....	35
102	7.8.1 Update literature review.....	35
103	7.8.2 Agreement to progress to guidance.....	35
104	8. Production of HTW guidance.....	35
105	8.1 The HTW Appraisal Panel.....	36
106	8.1.2 Meeting attendees.....	36
107	8.1.3 Format of meetings.....	36
108	8.1.4 Potential outcomes.....	37
109	8.2 Drafting the guidance.....	37
110	8.3 Guidance sign off.....	38
111	8.4 Publication and dissemination of guidance.....	38
112	8.5. Challenges to guidance.....	38
113	9. Impact and adoption of guidance.....	40
114	10. Review and re-assessment.....	40
115	11. Abbreviations.....	41
116		



117

## 118 **1. Purpose of this document**

119 This guide describes the processes that Health Technology Wales (HTW) follows when  
120 carrying out appraisals for health and social care.

121 The aim is to provide a high-level summary of our methods and processes in an accessible  
122 and transparent format for anyone with an interest in our work, to support engagement  
123 with the organisation and contribution to our work.

124

## 125 **2. Introduction to HTW and our process**

126 HTW is a national health technology assessment (HTA) body working to improve the quality  
127 of health and social care by issuing independent, authoritative guidance to health and  
128 social care providers in Wales, based on existing evidence regarding effectiveness and cost  
129 effectiveness. We do not undertake any primary research.

130 Our remit covers the evaluation of health and social care technologies and models of care  
131 and support. For health, this could include medical devices, diagnostics, procedures, and  
132 interventions by allied health professionals. For social care, this could include equipment  
133 and environmental design, or different models of care for supporting families, children,  
134 adults, and the workforce. HTW does not appraise medicines.

135 This document explains the process we use for appraisals, including:


- 136 • Initial topic submission and selection
- 137 • Production of a Topic Exploration Report (TER)
- 138 • Selection of topics for further work, in the form of an Evidence Appraisal Report  
139 (EAR)
- 140 • Production of an EAR
- 141 • Production of guidance

142 It also describes some of what happens after an appraisal: how we monitor the impact and  
143 adoption of our guidance, and the circumstances under which guidance may be changed  
144 or updated.

145



146 Our overall process is summarised in the flow diagram below.



147

148

149 Figure 1. Appraisals process flow diagram

150



### 151 **3: Who's involved and how**

152 This section outlines the people or groups involved in HTW's appraisal work. Their input  
153 will vary depending on the stage of the process, and will be detailed under the relevant  
154 process section of this document. Governance requirements such as declarations of  
155 interest (DoIs) and confidentiality statements are also covered.

156

#### 157 **3.1 Participants in the process**

##### 158 3.1.1 HTW decision-making committees, advisory groups, and staff

###### 159 3.1.1.1 HTW Staff

160 HTW's staff are a multidisciplinary group made up of Researchers, Health Economists,  
161 Information Specialists, and Patient and Public Involvement (PPI) professionals, working  
162 alongside staff with expertise in communications, project and programme management,  
163 and administration. Specific project teams are established for each appraisal topic.

164

###### 165 3.1.1.2 The Assessment Group

166 The Assessment Group oversees the production of HTW appraisal outputs, ensures  
167 methodological and scientific rigour in the work of HTW and adherence to agreed HTW  
168 processes. The Assessment Group also advises HTW on what technologies and models of  
169 care and support should be selected for appraisal, and agrees the research question(s)  
170 and methods for each appraisal.

171 Current membership of the Assessment Group, along with terms of reference, is published  
172 on the HTW website. The membership of the Assessment Group is determined by the HTW  
173 Chair and HTW Director, normally via nominations invited from relevant peer groups. As far  
174 as possible, membership endeavours to include representatives offering geographical  
175 spread across North, South West, South East, and Mid Wales, and representatives from  
176 both health and social care, including from each Local Health Board, the Welsh Ambulance  
177 Services NHS Trust, the Welsh Health Specialised Services Committee, and local  
178 authorities. Membership also includes two Public Partners from the Patient and Public  
179 Involvement Standing Group (PPISG). HTW is committed to the values of equality, diversity,  
180 and inclusion, and welcomes nominations for membership of the Assessment Group from  
181 all sectors of the community.

182 Although the Assessment Group seeks the views of organisations representing health and  
183 social care professionals, patients, carers, companies, and government, its guidance is  
184 independent.

185

###### 186 3.1.1.3 The PPISG

187 HTW's PPISG advises HTW on all aspects of our PPI work.

188 PPISG members have diverse experience and knowledge of patient and service-user  
189 involvement in research, PPI in HTA, patient networks and organisations across the UK and  
190 internationally, patient consultancy, and PPI processes across a range of different  
191 organisations.



192 Members are initially appointed for a period of 18 months before their role on the PPISG is  
193 formally reviewed. Normal appointment lengths are three years, after which a second  
194 review is conducted, with a maximum one-term renewal.

195

#### 196 3.1.1.4 The Appraisal Panel

197 The Appraisal Panel is the decision-making body of HTW that generates evidence-based  
198 guidance on health and social care technologies and models of care and support. This  
199 guidance is used to inform decisions about implementation and adoption of technologies  
200 and models of care and support appraised across Wales.

201 Current membership of the Appraisal Panel, along with terms of reference, is published on  
202 the HTW website. The membership of the Appraisal Panel is determined by the HTW Chair  
203 and HTW Director, normally via nominations invited from relevant peer groups. As far as  
204 possible, membership endeavours to include representatives offering geographical spread  
205 across North, South West, South East, and Mid Wales, and representatives from both  
206 health and social care, including from each Local Health Board, the Welsh Ambulance  
207 Services NHS Trust, the Welsh Health Specialised Services Committee, and local  
208 authorities. Membership also includes three Public Partners from the PPISG. HTW is  
209 committed to the values of equality, diversity and inclusion and welcomes nominations  
210 for membership of the Appraisal Panel from all sectors of the community.

211 Although the Appraisal Panel seeks the views of organisations representing health and  
212 social care professionals, patients, users of social care, informal carers, industry, and  
213 government, its guidance is independent.

214

### 215 3.1.2 Stakeholders outside of HTW

#### 216 3.1.2.1 Topic proposer

217 The topic proposer is the person who originally suggested the topic for the appraisal work  
218 programme. Anyone can suggest a topic that they think we could appraise, and we receive  
219 suggestions from people and organisations with a wide range of backgrounds, including  
220 clinicians or other health and social care professionals, commissioners, third sector  
221 organisations, industry representatives, academics, and the general public. Topics are  
222 normally submitted via a form on our website. We also use the NHS Innovation Service to  
223 identify health innovations. In this case, the person who submitted the topic to the NHS  
224 Innovation Service would act as the topic proposer.

225

#### 226 3.1.2.2 Industry representatives

227 These are representatives of manufacturers or suppliers of technologies relevant to the  
228 topic being appraised. These may be identified from our own research, or because they  
229 have registered an interest in a particular topic. Our advisory Industry User Group may also  
230 assist with identifying relevant organisations.

231



### 232 3.1.2.3 Subject experts

233 Subject experts provide independent advice and scrutiny during our work. Depending on  
234 the type of topic considered, they can be health and social care professionals, academic  
235 researchers, or other groups or individuals with expertise and experience relevant to the  
236 topic considered. Subject experts are identified from our own research and networks, or  
237 because they have registered an interest in a particular topic. As far as possible, HTW  
238 endeavours to include representatives from all relevant disciplines, offering geographical  
239 spread across Wales, as well as from other parts of the UK. We also approach relevant  
240 organisations or individuals representing health and social care professionals (for  
241 example, Royal Colleges, societies, clinical networks, directors of services in social care)  
242 and any relevant groups developing clinical and social care guidelines, or public health  
243 guidance.

244

### 245 3.1.2.4 PPI representatives

246 PPI provides a valuable dimension to our work. PPI can include individual patients, carers,  
247 and service users, along with organisations representing them, as well as public  
248 communities and patient groups.

249

### 250 3.1.2.5 Wider stakeholders

251 Depending on the topic, HTW may also involve other Welsh, UK-based, or international  
252 stakeholders. This can include collaboration or data sharing with other UK HTA bodies  
253 during topic identification and when planning an appraisal, and consulting stakeholders  
254 with a key role in implementing our guidance (such as Welsh Government, Local Health  
255 Boards, local authorities, or other social care providers) either during an appraisal or after  
256 guidance is produced.

257

## 258 **3.2 How participants are involved**

### 259 3.2.1 HTW decision-making committees, advisory boards, and staff

#### 260 3.2.1.1 HTW Staff

261 For each potential appraisal, HTW staff:

- 262 • Carry out initial assessment of suggested topics to determine whether they are  
263 within HTW's remit;
- 264 • Carry out exploratory research into the available evidence (a TER) to inform the  
265 Assessment Group on which topics should be selected for appraisal;
- 266 • Identify and liaise with specific stakeholders who can contribute to the appraisal  
267 process;
- 268 • Organise and manage meetings of the Assessment Group, the Appraisal Panel,  
269 and HTW's other relevant groups;
- 270 • Research and write the EAR;
- 271 • Support the Appraisal Panel in producing guidance on a topic, providing them  
272 with input and advice on interpretation of the evidence;





- 273       • Manage the timelines for each appraisal, communicating any changes to HTW's  
274       key groups and to other stakeholders.  
275

### 276 3.2.1.2 The Assessment Group

#### 277 The Assessment Group:

- 278       • Advises HTW on topic selection and prioritises topics for the appraisal work  
279       programme when necessary. Advises on horizon scanning and other potential  
280       sources of topic identification;  
281       • Agrees the research question(s) to be answered during an appraisal and the  
282       methods used to do so;  
283       • Reviews and quality assures EARs on behalf of the Appraisal Panel. Assures the  
284       Appraisal Panel on methodological and scientific rigour;  
285       • Agrees on stakeholder input and consultations required during an appraisal;  
286       • Reviews consultation comments on EARs, and advises HTW on revisions and  
287       further actions needed;  
288       • Assesses whether the EAR should be considered by the Appraisal Panel and  
289       guidance developed;  
290       • Inputs into changes or updates to HTW's methodology and processes.

291 Two Public Partners sit on the Assessment Group. Public Partner attendance at the  
292 Assessment Group is essential to:

- 293       • Ensure that any decisions made do not, or will not, unfairly impact on patients,  
294       users of social care, informal carers, individuals, and public communities;  
295       • Ensure that appropriate measures are taken to address issues of interest to  
296       patients, users of social care, informal carers, and the public;  
297       • Have oversight of HTW's PPI work;  
298       • Help ensure that the views of members of the public, carers, individuals and  
299       patients, and their families are considered.  
300

### 301 3.2.1.3 The PPISG

302 The PPISG has three main areas of work:

- 303       • determining the mechanism of PPI for all new topics,  
304       • advising on HTW's ongoing PPI activities, and  
305       • contributing to the writing of plain language summaries for all topics.

306 In addition, the PPISG supports the development of HTW's PPI process, mechanisms,  
307 documents and tools, events, and training. Members also assist with our engagement  
308 activities and advise on accessibility, diversity, and inclusivity of HTW's PPI and wider  
309 organisational activities.

310 Nominated Public Partners from the group are also members of the Assessment Group or  
311 the Appraisal Panel. If nominated Public Partners are not able to attend an Assessment  
312 Group or Appraisal Panel meeting, their place can be deputised by any member of the PPISG  
313 to make sure this perspective is considered appropriately at meetings.



314

#### 315 3.2.1.4 The Appraisal Panel

316 The Appraisal Panel:

- 317 • Considers the case for adoption of health and social care technologies and  
318 models of care and support that are undergoing appraisal. The Appraisal Panel  
319 provides recommendations on this in the form of HTW guidance, based on:
  - 320 - the evidence presented within HTW's EAR,
  - 321 o expert input, via comments on HTW's EAR and discussions with  
322 independent experts attending the Appraisal Panel meeting,
  - 323 - PPI, provided via the mechanisms determined by HTW's PPISG, and
  - 324 - the context of the topic within health and social care in Wales.

325 Three Public Partners sit on the Appraisal Panel on a rota basis, so that at least two  
326 representatives are present for each meeting. Public Partner attendance at the Appraisal  
327 Panel is essential to ensure:

- 328 • All elements of the PPI work gathered in the EAR are effectively and properly  
329 addressed by the Appraisal Panel during proceedings;
- 330 • There is governance over contributions from invited patient representatives;
- 331 • Any decisions made do not, or will not, unfairly impact on patients, carers,  
332 individuals, and public communities;
- 333 • The views of members of the public, informal carers, individuals, patients, users of  
334 social care, and their families are considered when decisions are made.

335

#### 336 3.2.2 Stakeholders outside of HTW

##### 337 3.2.2.1 Topic proposer

338 As and when required by the HTW project team, the topic proposer may be engaged in the  
339 development of the protocol, as well as assisting with any queries HTW staff may have at  
340 other stages. They will also be invited to participate in the expert review stage of the  
341 appraisal (see Section 7.7.3), subject to relevant DoI and confidentiality paperwork being  
342 completed.

343 The topic proposer may opt out of the process at any time, although the appraisal will still  
344 be undertaken.

345

##### 346 3.2.2.2 Industry representatives

347 Manufacturers or suppliers of relevant technologies will be invited to participate in the  
348 expert review stage of the appraisal (see Section 7.7.3), subject to relevant DoI and  
349 confidentiality paperwork being completed. Earlier in the appraisal process, their input  
350 may be sought on an ad-hoc basis in relation to protocol development and to clarify any  
351 other queries.

352 There is no requirement for industry experts to supply HTW with an evidence dossier for an  
353 appraisal. As with all our stakeholders, submission or highlighting of potentially relevant



354 evidence is welcomed and will be considered for inclusion in an appraisal on a case-by-  
355 case basis in line with the methods used to select evidence.

356 Please see expert review guidance (Section 7.7.3) for further details on eligibility and  
357 requirements.

358

### 359 3.2.2.3 Subject experts

360 Subject experts provide a view on the technology or model of care and support in relation  
361 to current practice, and help to put evidence used during the appraisal into context by, for  
362 example, commenting on its direct relevance to practice in Wales, and commenting on the  
363 importance of any uncertainties or limitations of the evidence.

364 Subject experts will be invited to participate in the expert review stage of the appraisal  
365 (see Section 7.7.3), subject to relevant DoI and confidentiality paperwork being completed.  
366 They may also be invited to attend the Appraisal Panel meeting to act as an independent  
367 expert. During this meeting, they will have the opportunity to give their views on the  
368 appraised topic and to respond to any queries that Appraisal Panel members may have.  
369 Subject experts are not involved in drafting or agreeing guidance, which is the sole  
370 responsibility of the Appraisal Panel.

371 Earlier in the appraisal process, subject expert input may be sought on an ad-hoc basis in  
372 relation to the protocol development and to clarify any queries.

373 Invited experts can opt out of the process at any time.

374 Please see expert review guidance (Section 7.7.3) for further details on eligibility and  
375 requirements.

376

### 377 3.2.2.4 PPI representatives

378 PPI seeks to incorporate the views, experiences, perspectives, and values of patients,  
379 individuals, carers, and their families to the appraisal process. We will actively seek to  
380 engage PPI input into our appraisals through our PPI mechanisms, but also welcome  
381 expressions of interest from individuals and groups. We also welcome topic submissions  
382 from patients, individuals, carers, and their families.

383

### 384 3.2.2.5 Other stakeholders

385 All stakeholders are able to register an interest in a topic via our website.

386 Completed guidance will be distributed to all stakeholders registered for our guidance  
387 alerts, as well as key NHS peer groups. Guidance will also be published on our website and  
388 disseminated via our social media channels.

389

## 390 3.3 DoIs and confidentiality

391 To ensure our appraisals are as unbiased and transparent as possible, we require self-  
392 reported DoIs from all stakeholders involved in the process. This includes all members of



393 HTW advisory and decision-making committees and staff, as well as anyone contributing  
394 to an EAR as a topic or industry expert, or from a PPI perspective. We also require  
395 confidentiality agreements from all staff and committee members, as well as anyone with  
396 access to draft copies of the EAR, such as those participating in expert review. Table 1  
397 provides an overview of how relevant Dols will be processed.

398

399 Table 1. Process for handling relevant Dols

Potentially relevant Dol from:	Action
Member of HTW staff	Considered by HTW staff with support from the Assessment Group if required. A staff member will not be involved in the project team for an appraisal where there is deemed to be a conflict of interest.
Member of decision-making and advisory groups	Considered by the Chair of the relevant group. If required, members with a relevant Dol will not take part in discussion of the relevant appraisal and may be required to leave the meeting for these discussions.
External reviewer of the EAR	Dols of subject experts or others invited to review the EAR will be reviewed by the HTW project team, who will ensure these are clearly documented. Dols do not prevent stakeholders from reviewing the EAR and submitting comments and feedback but they are taken into consideration when comments are reviewed and actioned. Any Dols will be documented in the collated summary of responses and shared with our decision makers. They may also be included in published documentation, but will not be specifically attributed to a named individual.

400

#### 401 4. Initial topic submission and selection

402 This section summarises the first stage of the HTW appraisal process, outlining what  
403 topics are covered within our remit and how we receive topics for consideration on our  
404 appraisal work programme.

405

##### 406 4.1 HTW's remit

407 HTW's remit covers any technology or model of care and support in health and social care  
408 that is not a medicine.

409 For health, this could include things like:

- 410 • medical devices,
- 411 • diagnostics,
- 412 • procedures,
- 413 • interventions by allied health professionals.

414 For social care, this could include things like:

- 415 • equipment,
- 416 • different models for supporting families, children, adults, and the workforce.



417 In Wales, appraisal of medicines is done by either the All Wales Medicines Strategy Group  
418 (AWMSG) or the National Institute for Health and Care Excellence (NICE).

419

## 420 **4.2 Sources of topics**

### 421 4.2.1 Suggest a Topic form

422 Anyone can suggest a topic for HTW appraisal through the Suggest a Topic form on our  
423 website.

424 We receive suggestions from a wide range of people, including the public. Our Suggest a  
425 Topic form aims to be suitable for everyone and should take around 15 minutes to  
426 complete.

427 Previous suggestions have come from people:

- 428 • working in health or social care,
- 429 • accessing health or social care services,
- 430 • providing care to a family member or friend,
- 431 • developing or researching technologies and models of care and support for health  
432 or social care,
- 433 • supporting people through third sector and voluntary organisations.

434 HTW staff are available to discuss potential topics with topic proposers before submission;  
435 however, all topics will still need to be formally submitted via the online Suggest a Topic  
436 form.

437

### 438 4.2.2 NHS Innovation Service

439 Companies or developers of a technology or model of care and support can also submit a  
440 topic to us through the NHS Innovation Service (link once live).

441 We review the NHS Innovation Service whenever we receive a notification that a relevant  
442 topic has been submitted. Topics may also be referred to other HTA organisations in the  
443 UK, in which case we will liaise with these bodies to ensure we are not duplicating each  
444 other's work.

445 All topics received via the NHS Innovation Service will then be considered in line with the  
446 process outlined in Section 4.3, as with any other topic referrals.

447 Communication with topic proposers for topics coming via the NHS Innovation Service will  
448 be undertaken via the NHS Innovation Service portal.

449

### 450 4.2.3 Other sources of topics

451 HTW also seeks topics through routes other than the referrals described above. We monitor  
452 guidance outputs of other UK HTA organisations, and consider where similar guidance may  
453 be useful for health and social care in Wales. We also consult with stakeholders on broader  
454 priorities or areas of unmet need for health and social care in Wales and use this to identify  
455 potential topics.



456 When identified, such topics will be considered in line with our standard topic  
457 prioritisation processes as outlined in Section 6.

458

### 459 **4.3 Topic selection for further exploration**

#### 460 4.3.1 Topic eligibility for topic exploration

461 Topics must meet certain criteria to be potentially suitable for appraisal. We will consider  
462 a topic for appraisal if:

- 463 • It is a technology or model of care and support that falls within HTW's remit,
- 464 • It has the potential to directly impact patients, users of social care, or informal  
465 carers, and
- 466 • It has appropriate regulatory approval, or is expected to have regulatory approval  
467 within the next 12 months.

468 A topic will not usually be considered suitable for appraisal if:

- 469 • it is a medicine,
- 470 • use of the technology or model of care and support does not directly influence  
471 patient outcomes, wellbeing, or experience,
- 472 • it is still a prototype or still under development.

473 Although we would not usually consider topics that meet any of these exclusion criteria  
474 suitable for full appraisal, we may still produce a TER (see Section 4.3). This provides health  
475 and social care stakeholders in Wales with a high-level evidence overview, without  
476 developing an EAR or guidance.

477

#### 478 4.3.2 Reviewing topic submissions for eligibility and further appraisal

479 New topic submissions are reviewed by HTW staff and are used to determine whether the  
480 topic meets HTW eligibility criteria (see Section 4.3.1). A member of the HTW team will  
481 contact the topic proposer if further clarification or information is needed to determine  
482 this.

483 If the topic meets HTW's eligibility criteria, the topic proceeds to topic exploration and a  
484 TER is produced.

485 We aim to review topics submitted within a two-week period; however, decision making  
486 may be delayed if there are any queries or uncertainties that need to be explored by  
487 carrying out initial background research, or by contacting the topic proposer or other  
488 stakeholders.

489

#### 490 4.3.3 Topics not suitable for topic exploration

491 If a topic does not meet our eligibility criteria, it may be directed to our Signposting Group  
492 (see Glossary). If it is established that this route may be suitable, permission for referral  
493 will be requested from the topic proposer.



494 If permission is agreed, the Signposting Group will be sent details of the topic proposed,  
495 with a request to respond in three weeks, and will provide HTW with any suggestions for  
496 potential next steps for the topic proposer. HTW will collate these comments and  
497 communicate them to the topic proposer. The Signposting Group may not always be able  
498 to provide any suggestions for further action if a topic does not fall within the scope of  
499 individual members.

500 HTW may also flag the support available via the HTW Scientific Advice Service (see  
501 Glossary).

502

## 503 **5. Production of a TER**

504 This section outlines the first type of report we produce on a topic, the TER. It covers the  
505 type of information we include in this report, and how we get this information. A TER is used  
506 by HTW staff and the HTW Assessment Group to determine whether further appraisal work  
507 is appropriate, and whether it would be likely that guidance could be produced using  
508 available evidence.

509

### 510 **5.1 TER contents**

511 TERs are designed to provide a high-level summary of a topic and an overview of the  
512 evidence available. The main objectives are to:

- 513 • Determine the quantity of evidence available for a technology or model of care and  
514 support,
- 515 • Identify any gaps or uncertainties in the evidence,
- 516 • Inform decisions on whether the topic warrants further appraisal by HTW, in the  
517 form of an EAR.

518 The TER focusses on the quantity of evidence, the type of evidence (for example, systematic  
519 reviews, randomised controlled trials [RCTs], observational studies) and any uncertainties  
520 or gaps in the evidence. If gaps are identified, the Researcher will check for any ongoing  
521 studies that may address these gaps.

522 The TER will list any evidence identified, typically in the following areas:

- 523 • HTAs and guidance,
- 524 • Evidence reviews and economic evaluations,
- 525 • Individual studies,
- 526 • Ongoing research.

527 As part of preparing the TER, HTW staff will also draft potential research questions and  
528 selection criteria for the topic if it were to progress to full EAR.

529

### 530 **5.2 TER process**

531 Searches for evidence to inform a TER are carried out by a single Researcher, with  
532 Information Specialist input if needed. The purpose of the search is to:



- 533
- Ascertain whether there is published evidence that could be used to address the question of interest as understood from the topic referral form;
- 534
- Provide a non-exhaustive overview of the types of evidence that exist, and any uncertainties or gaps in the evidence.
- 535
- 536

537 Evidence is gathered by a high-level scan of the literature. This is not a systematic search, although similar sources to those used for a full systematic literature search would be searched and checked. This means that a TER may not cover all the evidence that exists on a topic, particularly in cases where the evidence base is extensive. Instead, the aim is to give an overview of the evidence that exists, sometimes with a focus on sources that are most recent or relevant. Searches and the evidence presented in the TER may also prioritise certain types of evidence. For example, if robust and recent sources of secondary evidence are identified that address the question of interest, the TER may only report these and not the findings of individual studies. Each TER will briefly explain the methodology used for searching and justify any inclusion or omission of sources of evidence.

538

539

540

541

542

543

544

545

546

547 In some cases, the Researcher may contact the topic proposer to clarify any outstanding queries about the topic before or during topic exploration. Where initial searching indicates that the evidence covers a wide range of different populations, settings, or comparisons, we may also work with the topic proposer to identify one or more areas of focus. It may also be appropriate for the Researcher to contact other stakeholders if they have any specific questions at this stage.

548

549

550

551

552

553 The completed TER is then reviewed for quality assurance purposes by a senior member of the HTW team and any required amendments completed.

554

555 It is anticipated that it takes around four weeks for a TER to be prepared. The draft TER will be sent to the topic proposer before publication. This is an opportunity for the topic proposer to highlight any perceived inaccuracies or errors in the report, including interpretation of the evidence, and to highlight any additional sources of evidence they believe should be included. The topic proposer will be given two weeks (10 working days) to respond. Comments on the TER should be submitted in writing to ensure they are documented clearly along with our responses to them.

556

557

558

559

560

561

562 If the topic proposer is not best placed to comment on the report (for example, if they are not an expert in the use of the technology or model of care and support, or the relevant area of health and social care), they may also nominate another representative to comment on the TER and respond to our queries. This person could be nominated by the topic proposer or sought by HTW.

563

564

565

566

567 HTW staff will review any comments and, if appropriate, revise the TER before publication. If necessary, HTW staff will discuss any proposed changes with the Assessment Group. HTW may also send the topic proposer a summary of responses to their comments and any changes made.

568

569

570

571 Finalised TERs will be published on the HTW website once they have been considered for prioritisation onto the appraisal work programme by the Assessment Group, along with the outcome of whether a topic has progressed or not. Timescales for publication will vary as this will be dependent on when a topic has been reviewed by the Assessment Group? at an HTW prioritisation meeting. A notification email will be sent to the topic proposer to advise when the report is available online.

572

573

574

575

576

577





## 578 **6. Topic selection and prioritisation for the appraisal work programme**

579 This section outlines the process used to select topics for the appraisal work programme,  
580 including how we engage stakeholders at this stage.

581 Each TER is used by HTW staff and the HTW Assessment Group to determine whether  
582 further appraisal work is appropriate, and whether it would be likely that guidance could  
583 be produced using this evidence. This step may also involve prioritising topics for addition  
584 to the appraisal work programme when necessary.

585

### 586 **6.1 Why is prioritisation important?**

587 HTW only has capacity to carry out a finite number of appraisals each year, according to  
588 staff resources and scheduling of sufficient meetings of the Assessment Group and  
589 Appraisal Panel. In circumstances where the number of potential topics suitable for the  
590 appraisal work programme exceeds the capacity of the appraisal work programme,  
591 prioritisation is used to rank topics by their likely impact and importance to health and  
592 social care in Wales, with the highest-ranking topics taken onto the appraisal work  
593 programme first.

594

### 595 **6.2 Prioritisation process**

596 Once a TER is completed, it is reviewed by HTW staff and the Assessment Group to  
597 determine if it is appropriate for progression onto the appraisal work programme.

598 HTW staff will use the TER to establish if the topic is suitable for full appraisal. Reasons a  
599 topic may be deemed unsuitable include:

- 600 • There is insufficient evidence for an appraisal,
- 601 • There is ongoing research likely to be critical to decision making,
- 602 • The same topic is currently undergoing appraisal by another UK HTA organisation.

603 Where appraisal is ongoing elsewhere in the UK, HTW will not commence work on this topic  
604 at least until appraisal work elsewhere has been completed, to avoid duplication and  
605 research waste. Depending on the type of appraisal, HTW will then consider whether its  
606 findings are applicable in Wales, or whether the work can be adapted to produce guidance  
607 for Wales.

608 In some cases, we may decide not to progress a topic at this stage. This may be where there  
609 is very little evidence, the evidence indicates the technology or model of care and support  
610 is unlikely to offer advantages over current care, or the topic proposer and HTW staff are  
611 unable to define a suitable research question for a more detailed evidence search. Whilst  
612 a topic proposer's input will be considered, the Assessment Group's decision is final.

613 If a topic is considered suitable based on initial screening, it is then considered in more  
614 detail by HTW staff, who will assess it in terms of:

- 615 • Impact: The potential for the technology or model of care and support to have an  
616 impact on outcomes (benefits and harms);
- 617 • Budget impact: The impact of the technology or model of care and support on  
618 health and care spending;



- 619 • Burden of disease: The nature of the condition involved, and the size of the
- 620 population that would be affected by the technology or model of care and support;
- 621 • Stakeholder interest: The level of known or anticipated demand for the technology
- 622 or model of care and support, and the likelihood that advice will be adopted;
- 623 • Equity: The potential of the technology or model of care and support to introduce,
- 624 increase, or decrease equity.

625 In addition to monthly Assessment Group meetings, a separate prioritisation meeting is  
 626 scheduled on a quarterly basis. It is at this meeting that the Assessment Group agrees  
 627 which topics should be taken onto the appraisal work programme, and the priority with  
 628 which they should be considered.

629 A summary of all topics considered for prioritisation is submitted to the Assessment  
 630 Group, along with copies of TERs for review.

631 All submitted topics will be considered by the Assessment Group, including those which  
 632 did not progress through initial screening to ensure the Assessment Group agree with the  
 633 recommendations of HTW staff.

634 To aid the prioritisation process, topic proposers for potential topics may be invited to the  
 635 meeting to briefly introduce and discuss their technology or model of care and support  
 636 and the potential benefits of an appraisal, undertaking a question-and-answer session  
 637 with Assessment Group members.

638 Topics will be discussed in detail, and a decision will be made by the Assessment Group  
 639 based on the TER content, HTW's prioritisation assessment, and discussion with the topic  
 640 proposer.

641 The Assessment Group may make one of the following decisions, outlined in Table 2.

642

643 Table 2. Potential topic outcomes following Assessment Group discussion

<b>Topic prioritised for HTW appraisal</b>	The topic will progress to the appraisal work programme.
<b>Topic is not suitable for HTW appraisal</b>	The topic will not progress past the TER stage. The topic proposer is welcome to resubmit the topic for further assessment should they become aware of any changes in the future, for example, publication of new evidence.
<b>Further information is needed</b>	Topic is potentially suitable for EAR and guidance, but more information is needed before a final decision can be made. Questions will be addressed outside of the meeting, and the topic will be resubmitted to a future prioritisation meeting.
<b>Topic potentially suitable for appraisal, but not prioritised at this time</b>	There may be occasions when a topic is potentially suitable for appraisal, but other topics under consideration are deemed a higher priority and there is not a slot on the appraisal work programme at that time. The topic will be reconsidered in the next prioritisation meeting.

644

645 Following the prioritisation meeting, topic proposers will be notified of the Assessment  
 646 Group's decision via email. The decision will also be published on the website alongside



647 the completed TER. This process can take around four weeks as queries are addressed and  
648 TERs finalised for publication.

649

## 650 **7. Production of an EAR**

651 This section outlines the various stages of producing our second type of report, the EAR,  
652 and describes the information included in more detail.

653 Once a topic is selected for the appraisal work programme, an EAR will be developed. The  
654 EAR summarises:

- 655 • The context or area of unmet need, and how the technology or model of care and  
656 support aims to improve outcomes in this area;
- 657 • The background on current care in this area, and if this varies within Wales or  
658 across the wider UK;
- 659 • The synthesis of available evidence on the effectiveness of the appraised  
660 technology or model of care and support;
- 661 • The available economic evidence on the technology or model of care and support  
662 and any economic analysis carried out by HTW;
- 663 • The PPI input and evidence relevant to the topic;
- 664 • Any other relevant factors that would need to be considered if the technology or  
665 model of care and support were to be adopted.

666 To identify evidence for the report, we conduct a type of review called a rapid evidence  
667 review. Whilst there is no universally accepted definition of rapid evidence reviews, it is  
668 generally accepted that they involve a more streamlined, accelerated version of systematic  
669 review [Garrity Cochrane RRG <https://doi.org/10.1016/j.jclinepi.2020.10.007>].

670 The EAR is considered, along with other supporting documents and information, by our  
671 Appraisal Panel in the development of HTW guidance.

672

### 673 **7.1 Planning the appraisal**

674 Once a topic is accepted onto the appraisal work programme, a team will be appointed  
675 comprising:

- 676 • a Health Economist
- 677 • a Senior Health Economist
- 678 • a Health Services Researcher
- 679 • a Senior Health Services Researcher
- 680 • a PPI Manager
- 681 • a Communications Manager
- 682 • a Project Manager.

683 This is referred to as the HTW project team.

684 The team will start by developing a detailed plan for the appraisal. This includes defining  
685 the scope of the project by drafting a topic protocol and economic plan, determining the



686 most appropriate methods of patient, service user, and public engagement, and  
687 establishing timescales for the project.

688 It normally takes around six weeks from a topic being accepted onto the appraisal work  
689 programme to plans being agreed and finalised, though this may vary dependent on  
690 Assessment Group meeting dates.

691

#### 692 7.1.1 Topic protocol

693 The topic protocol outlines how we plan to search for and identify evidence on a topic that  
694 has been accepted onto the appraisal work programme. This ensures the evidence  
695 included, and the justification for this, is transparently documented and selected in a way  
696 that minimises bias.

697 The main objectives of the topic protocol are to:

- 698 • Give a brief overview of the topic in question,
- 699 • Outline the proposed research question,
- 700 • Provide the study selection criteria, which are used to identify relevant evidence.

701 A protocol will usually include one review question. In some exceptional cases, two related  
702 questions may be considered. The title of the EAR should reflect the content of the review  
703 question(s).

704

##### 705 7.1.1.1 Protocol contents

706 The protocol provides specific detail on what is in and out of scope for the topic, covering  
707 areas including selection criteria, study design, and the type of evidence that will be  
708 considered.

709 The selection criteria normally include the following:

- 710 • The target population
- 711 • The intervention of interest, that is, the technology or model of care and support  
712 that has been submitted for appraisal
- 713 • The comparator or comparison being made. Usually, comparators are limited to  
714 those that are of most interest and best represent standard care in Wales
- 715 • The outcomes of interest. As HTW undertake rapid evidence reviews, we focus on  
716 the outcomes that are considered most important and relevant for decision  
717 making in Wales
- 718 • With diagnostics, a reference standard is also included.

719 In addition to being used to select evidence, the protocol determines what evidence will be  
720 reported in the EAR: reporting on effectiveness of a technology or model of care and support  
721 should encompass all elements of the eligibility criteria (for example, all possible target  
722 populations, outcomes, and possible control or comparison groups of interest) specified  
723 in the protocol. Where no evidence is found for a particular criterion, this should be clearly  
724 stated alongside the evidence found.

725 Topic protocols are agreed with our Assessment Group to ensure they are methodologically  
726 robust and their scope is appropriate. On occasion, based on Assessment Group input, HTW



727 may seek stakeholder advice on the development of the protocol, requesting views from  
728 the stakeholders or the topic proposer on planned criteria. In all cases, draft protocols will  
729 be circulated to our Stakeholder Forum (see Glossary) for comment to ensure they reflect  
730 the priorities of health and social care in Wales.

731

#### 732 7.1.2 Economic plan

733 HTW carries out reviews of the existing economic literature as part of the appraisal  
734 process. Where the existing economic evidence is inadequate or inconclusive, additional  
735 economic analysis is often required to assess cost effectiveness. However, conducting de  
736 novo economic analyses is time consuming and so it may not be practical to do this for  
737 every topic appraised by HTW. There is therefore a need to prioritise our efforts on those  
738 topics where economic analysis has the potential to be of most value.

739 We develop an economic plan to identify the likely priority level for a topic and this informs  
740 the economic analysis that will be undertaken. The economic plan provides a clear  
741 framework for making considerations on the likely priority level as well as an outline of the  
742 proposed methods for evaluating cost effectiveness. This framework considers the  
743 expected budget impact, whether the cost effectiveness of the intervention is currently  
744 uncertain, and whether this uncertainty could feasibly be reduced by undertaking de novo  
745 economic analysis.

746

#### 747 7.1.3 PPI mechanism

748 PPI is a crucial aspect of all our appraisal work. The most appropriate way to undertake PPI  
749 will vary for each topic.

750 When a topic is accepted onto the appraisal work programme, the PPISG determines what  
751 the appropriate mechanism of PPI is for that topic. This is called the PPI mechanism plan.  
752 At this stage, we may engage early with patient or service-user organisations to inform our  
753 decision on the most appropriate approach. In some cases, the PPISG will decide that a  
754 topic is unsuitable for detailed PPI activity.

755 The PPI mechanism allows for several approaches to gathering PPI for an appraisal,  
756 including:

- 757 • submissions from patients, users of social care, and informal carers (via a patient  
758 or carer organisation)
- 759 • questionnaires or surveys (via a patient or carer organisation)
- 760 • focus groups (via a patient or carer organisation)
- 761 • literature searches that look specifically for PPI evidence.

762 For each appraisal, the PPISG can select one or more approaches, and HTW can engage with  
763 multiple patient and service user organisations. If the chosen approaches are  
764 unsuccessful, for example if HTW is unable to engage with suitable patient and service-  
765 user organisations, the PPISG may decide to amend the mechanism plan. This flexibility  
766 ensures that HTW appraisals include PPI wherever possible and in the most appropriate  
767 form.

768



#### 769 7.1.4 Timelines and project plans

770 All topics taken onto the appraisal work programme will receive a detailed project plan  
771 outlining key deadlines and milestones, in particular noting when the topic will be  
772 considered for guidance by our Appraisal Panel.

773 Factors considered when planning timelines include:

- 774 • Nature and complexity of the evidence review, economic analysis, and PPI work  
775 required
- 776 • Anticipated volume and complexity of published evidence
- 777 • Any known external dependencies, such as publication of major studies that will  
778 impact findings
- 779 • Prioritisation of topics on the appraisal work programme  
780 Overlap with other topics on the appraisal work programme

781

#### 782 7.1.5 Sign off

783 Around six to eight weeks after a topic has been accepted onto the appraisal work  
784 programme, the topic protocol, economic plan, PPI mechanism, and proposed timelines  
785 will be submitted to the Assessment Group for sign off. This is to ensure they reflect the  
786 priorities of health and social care in Wales, and are methodologically robust.

787

##### 788 7.1.5.1 Protocol amendments

789 On occasions, it may be necessary to amend aspects of our proposed approaches and  
790 methods after the appraisal has commenced. Examples of when this could be necessary  
791 include:

- 792 • when input from subject experts indicates a need to focus on particular aspects  
793 of the planned research question (such as narrowing to a particular population  
794 where there is the most unmet need, or amending the outcomes for which data  
795 are collected and reported to ensure these are the ones that matter most to  
796 people).
- 797 • where initial searches indicate the availability of high volumes of evidence,  
798 restricting the evidence that is searched for or synthesised to focus on that which  
799 offers the most certainty, or is most relevant to decision making.
- 800 • amending the planned evidence searches to ensure they identify evidence to  
801 inform health economic analysis, or planned mechanisms of PPI.

802 Such changes may result in amendments to the protocol or economic plan. Any such  
803 changes will be agreed by the Assessment Group, and documented, along with the  
804 rationale for the amendments, in our published EAR.

805

## 806 **7.2 Evidence identification**

807 Once the methods for an appraisal are planned, as much evidence as possible relevant to  
808 the appraisal needs to be identified. This evidence can come from our own searches (see  
809 Section 7.2.1) or from other sources (see Section 7.2.2).



810

## 811 7.2.1 Searching for the evidence (literature searching)

812 We adopt a flexible approach for the searches we run to support the confines of our rapid  
813 evidence review timelines. Literature searches for our rapid evidence appraisals aim to  
814 identify the best available evidence to address the review question, without producing an  
815 unmanageable volume of results. In this section we outline how we plan, execute, and  
816 document our literature searching activities.

817

### 818 7.2.1.1 Planning the search

819 Literature search strategies are directly informed by the selection criteria listed within  
820 the appraisal protocol.

821

### 822 7.2.1.2 Sources

823 HTW information specialists have developed and maintain checklists specific to the type  
824 of search being undertaken, based on the characteristics of the technology or model of  
825 care and support, including whether it is used in health or social care settings. The  
826 checklists include core bibliographic databases (searched for all appraisals), specialised  
827 databases (used as and when considered appropriate to the topic or research area), and  
828 clinical trials registries, as well as relevant grey literature sources and websites. The  
829 checklists have been developed to ensure adequate coverage of the relevant literature and  
830 to balance comprehensiveness with pragmatism.

831

### 832 7.2.1.4 Writing and running the search

833 Searches are written and run by HTW's information specialists.

834 As well as the protocol, other sources used to inform search development include the TER  
835 and information provided by the topic proposer. These, and any relevant literature they  
836 contain, are used to develop specific search terms. Other relevant published search  
837 strategies may also be used to inform the search strategy.

838 Development of the strategy is an iterative process, including testing different potential  
839 search terms and checking the results for relevancy, as well as ensuring known relevant  
840 records are retrieved by the search. Quality assurance of literature search strategies is also  
841 undertaken, either internally within the information specialist team at HTW or via our  
842 external networks of information or subject specialists.

843 The final search strategy for each source is then run and the retrieved results downloaded  
844 or manually recorded. All the retrieved results are processed together and saved using  
845 reference management software.

846

### 847 7.2.1.5 Updating searches prior to publication

848 Literature searches for EARs are re-run towards the end of the development timeline, to  
849 identify any further evidence that has been published since the search was last run.



850

#### 851 7.2.1.6 Documenting the search

852 To ensure transparency and reproducibility of the search, a search report is produced for  
853 the full search and update(s). This ensures that there is a record of all sources included in  
854 the search, as well as details of the database host and its date range. In addition, any key  
855 decisions pertaining to the search are recorded, including decisions on search methods,  
856 specific terms that are included or excluded, date limits, and study design filters used. The  
857 full search strategies for each source are also included along with numbers of results  
858 retrieved.

859 A summary of the key points from the search report (including the date of both the main  
860 and update searches) is included in the HTW EAR. The Medline search strategy is also  
861 included in the EAR and other search strategies are available on request.

862

#### 863 7.2.2 Other sources

864 We will also consider, if appropriate, unpublished sources provided by stakeholders such  
865 as primary studies, economic modelling, or audit data. As with sources identified from our  
866 literature search, the HTW project team will select what evidence should be included based  
867 on our inclusion and exclusion criteria.

868 We aim to make all information we use in our decision making publicly available, so we  
869 will work with the authors or owners of unpublished sources to incorporate these data,  
870 without redaction, into the published version of our EAR wherever possible. Confidential  
871 information is considered in exceptional circumstances with appropriate justification  
872 and, where this is included, it is redacted from the published version of our documentation.

873

### 874 **7.3 Selection, synthesis, and presentation of effectiveness evidence**

875 For every appraisal, we carry out a rapid evidence review, to assess the effectiveness of the  
876 appraised technology or model of care and support. This review aims to identify all relevant  
877 evidence, assess its reliability and certainty, and summarise the overall effectiveness of  
878 the technology or model of care and support, in comparison with current treatment or care  
879 options.

880 For HTW rapid evidence reviews, the key steps in the evidence selection and synthesis  
881 process are:

- 882 • Selecting sources of evidence from the literature search according to the  
883 predefined inclusion and exclusion criteria in the protocol (see Section 7.1.1);
- 884 • Extracting relevant data from relevant sources of evidence;
- 885 • Synthesising the evidence.

886 These steps are common to all rapid evidence reviews, whether conducted by HTW or  
887 others. Earlier steps in the process, such as defining the research question, the topic  
888 protocol, and searching for evidence, are covered above in Sections 7.1.1 and 7.2.1.

889 HTW's methods for evidence selection and synthesis are based on and adapted from  
890 [Garrity Cochrane RRMG, <https://doi.org/10.1016/j.jclinepi.2020.10.007>] and [NICE Guidelines





891 Manual PMG20, <https://www.nice.org.uk/process/pmg20>]. An overview of the process is  
892 given in the following sections.

893

### 894 7.3.1 Study selection

895 A single Researcher carries out evidence selection based on the criteria outlined in the  
896 protocol (see Section 7.1.1). During quality assurance, a second Researcher checks the  
897 choice of included studies against the protocol and may also check excluded full texts and  
898 reasons for exclusion.

899

#### 900 7.3.1.1 Types of evidence included

901 We consider all types of evidence as potentially relevant to our rapid evidence reviews.  
902 However, we give priority to evidence that compares the effectiveness of a technology or  
903 model of care and support with current treatment or care options, and that measures  
904 effectiveness in as unbiased a manner as possible. If we identify relevant and well-  
905 conducted RCTs, we may choose to report only results from these and not from non-  
906 randomised or observational studies. Similarly, where RCTs are unavailable or not feasible,  
907 we will look for other sources of evidence from non-randomised or observational studies  
908 that compare the technology or model of care and support of interest with current practice  
909 or standard care. We will only include data from single-arm studies (where there is no  
910 control group) if no comparative evidence is available. For appraisals relating to social care  
911 topics, it may be appropriate to include UK-based non-randomised or observational  
912 studies alongside RCTs to explore the generalisability of findings.

913 We will also prioritise evidence from well-conducted secondary studies, such as  
914 systematic reviews or HTAs undertaken by other agencies, where these are available.  
915 Depending on their exact relevance to our work, they can be used as a source of existing  
916 individual studies (helping to limit the amount of literature searching carried out by HTW  
917 Researchers) or as a source of study design and outcome data to be used directly in our  
918 own evidence synthesis.

919

### 920 7.3.2 Data extraction

921 A single reviewer extracts data from selected, relevant studies. Data extraction is limited  
922 to a minimal set of required data items, usually covering the design of each study, the  
923 characteristics of study participants, and the outcomes measured. If necessary, a pilot of  
924 data extraction is done to resolve or clarify any issues or uncertainties.

925 Where available, the reviewer uses data from existing relevant and well-conducted  
926 systematic reviews to reduce the time spent on study selection and data extraction. For  
927 example, where a relevant and well-conducted systematic review is found, we may report  
928 the findings from this review and only search for and include individual studies published  
929 since the searches for this review were carried out.

930 During quality assurance (see Section 7.7.1), a second Researcher checks at least a  
931 proportion of data extraction. Volume of evidence and timescales for review production  
932 mean checking of all data is not always possible.



933

#### 934 7.3.2.1 Assessment of certainty of the evidence

935 Critical appraisal is not formally reported using tools or checklists, and full risk-of-bias  
936 judgements for each source of evidence are not documented. However, an informal  
937 assessment is made by members of the HTW project team, and any issues with risk of bias  
938 or evidence certainty are reported either alongside study details or as part of the  
939 Conclusions and Summary.

940

#### 941 7.3.3 Synthesis

942 Evidence is usually synthesised narratively. Meta-analysis adds to the time and resource  
943 needed to conduct an evidence review, so we will only carry out meta-analysis when it is  
944 feasible, appropriate, and relevant to decision making, for example:

- 945 • An existing meta-analysis is available and it is appropriate and feasible to update  
946 it to incorporate any newer individual studies published since it was carried out.
- 947 • An existing meta-analysis is available but includes studies that are not relevant to  
948 our evidence review, and it is appropriate and feasible to carry out pooled analysis  
949 using only the studies of relevance to our review.
- 950 • There are multiple individual studies that are similar enough in their  
951 characteristics and design to minimise the potential for heterogeneity and report  
952 consistent outcomes that can be pooled without data transformation.

953 The way that effectiveness evidence is structured in each EAR will vary, depending on the  
954 topic, the type of evidence, and the volume of evidence. However, all EARs include:

- 955 • The selection criteria used to search for and identify relevant evidence for the  
956 review.
- 957 • An explanation of the relevant evidence identified, including any decisions on how  
958 existing systematic reviews or other sources of secondary evidence have been  
959 adapted, and decisions on whether to include only studies of a certain design.
- 960 • The design and characteristics of the evidence, including aspects that affect their  
961 reliability, certainty, or relevance to the review question.
- 962 • The evidence available for each outcome of interest, and the sources from which  
963 this was derived.
- 964 • Judgements on the overall certainty and reliability of the evidence, including any  
965 'evidence gaps' where no or very limited evidence was found to address part of the  
966 review question or decision problem.

967

#### 968 **7.4 Economic evidence**

969 HTW EARs include a review of existing economic evidence identified as part of the  
970 systematic review and an overview of any original economic analyses undertaken to  
971 inform the review question. Both the critical appraisal of existing studies and the  
972 development of original economic analyses are informed by the NICE Reference Case (see  
973 Glossary).

974



975 7.4.1 Types of economic evaluation

976 Economic evaluations aim to provide a comparative analysis of alternative courses of  
977 action in terms of both their costs and consequences (Drummond). However, economic  
978 analyses vary in terms of the costs and consequences they consider, and these differences  
979 can be used to classify the different types of analyses. Different decision problems may  
980 merit different types of economic evaluation.

981 In situations where a new intervention is known to be associated with higher effectiveness  
982 than current standard care, a simple cost analysis may be the only requirement. However,  
983 if the intervention is also associated with a higher cost, a more complex modelling  
984 approach, such as cost-utility analysis, may be necessary.

985 The type of economic evaluation that will be undertaken by HTW depends on the level of  
986 available evidence and the expected outcomes of the new intervention. The main types of  
987 economic evaluations are described below:

- 988 • Cost-utility analysis: Consequences are expressed in terms of quantity and  
989 quality of life using quality-adjusted life years (QALYs).
- 990 • Cost-effectiveness analysis: Consequences of interventions are measured in non-  
991 monetary terms using a single outcome. Interventions are compared as cost per  
992 unit of effectiveness (for example, cost per life year gained).
- 993 • Cost-consequence analysis: Costs and consequences of different interventions  
994 are compared but outcomes are not summarised in a single measure or in  
995 financial terms.
- 996 • Cost-benefit analysis: Costs and outcomes of an intervention are expressed in  
997 monetary terms.
- 998 • Cost-minimisation analysis: Costs of interventions that are equally effective are  
999 compared to determine the least costly approach.

1000

1001 7.4.1.1 Choice of comparator

1002 An economic evaluation should include all relevant comparators to the intervention in  
1003 question. It is particularly important to include those interventions being routinely used in  
1004 the NHS and in social care in Wales.

1005

1006 7.4.1.2 Perspective of analysis

1007 The NHS and personal social services perspective will be adopted in most economic  
1008 analyses. This perspective is chosen as it is the most applicable to the appraisals that HTW  
1009 typically undertakes. However, wider perspectives will be considered for technologies that  
1010 are expected to have significant health and cost consequences beyond the NHS, such as  
1011 social care technologies or models of care and support.

1012

1013 7.4.1.3 Time horizon

1014 The time horizon selected for analysis should be long enough to reflect all important  
1015 differences in costs and outcomes between the interventions being compared. For  
1016 example, if a new intervention is expected to reduce a patient's risk of stroke, this is likely



1017 to have impacts on outcomes for the lifetime of the patient, and so a lifetime horizon  
1018 should be modelled.

1019

#### 1020 7.4.1.4 Discounting

1021 Base case results of analyses should be discounted at an annual rate of 3.5% for both costs  
1022 and benefits.

1023

#### 1024 7.4.2 Model inputs

1025 Economic analyses are underpinned by different types of evidence for the alternative  
1026 courses of action being evaluated. For example, this could include evidence relating to:

- 1027 • disease prognosis or developing need for care;
- 1028 • the relationship between short- and long-term outcomes;
- 1029 • quality of life;
- 1030 • adverse events;
- 1031 • resource use and costs.

1032 While economic analyses should be populated with the best available evidence, these data  
1033 are often from disparate sources and vary in their applicability and quality. HTW  
1034 undertakes a systematic review to identify effectiveness evidence as outlined in Section  
1035 7.3. However, as HTW EARs follow a rapid evidence review model, it is not possible to  
1036 undertake systematic literature reviews to inform every model input. Economic analyses  
1037 should be populated with the best quality evidence available that underpins the research  
1038 question. In addition to the systematic review to identify effectiveness evidence (Section  
1039 7.3), additional methods are used to identify model inputs, which may vary for different  
1040 research questions.

1041

#### 1042 7.4.2.1 Effectiveness

1043 Effectiveness inputs should reflect the effectiveness evidence presented in the EAR as far  
1044 as possible and any deviations from this approach should be highlighted for the  
1045 consideration of decision makers.

1046 Typically, the key effectiveness input for an economic evaluation is an estimate of the  
1047 relative effectiveness of the intervention in comparison with standard care, often  
1048 expressed as a relative risk or hazard ratio. The outcomes considered vary depending on  
1049 the topic under consideration but should include those aspects expected to have an  
1050 impact on costs, survival, or quality of life. For example, an economic analysis considering  
1051 an intervention for cancer would likely include outcomes such as overall survival, disease-  
1052 specific survival and treatment-related adverse events.

1053 In addition to considering any disease-specific mortality, we typically consider  
1054 background mortality for the general population, which we source from Office for National  
1055 Statistics (ONS) life tables.

1056



1057 7.4.2.2 Quality of life

1058 Where possible, quality-of-life data for the health economic model are sourced from the  
1059 effectiveness evidence identified in the EAR. However, in most cases, such data are not  
1060 identified and alternative approaches are required. There are several resources that can be  
1061 used to identify appropriate values, such as the Tufts Cost-Effectiveness Analysis Registry  
1062 and the NICE Decision Support Unit's technical support documents. Alternatively, values  
1063 may be sourced from published economic analyses considering the same or closely related  
1064 populations.

1065 Generic measures of quality of life are preferred for economic analyses as they are  
1066 applicable across disease areas and conditions. There is a particular preference for the  
1067 EuroQol Five-Dimensions (EQ-5D) survey. However, alternative measures such as the 36-  
1068 Item Short Form Health Survey (SF-36) may be used and mapped to EQ-5D using published  
1069 mapping algorithms. Where possible, quality of life should have been reported directly by  
1070 people using the service or their carers.

1071 In some cases, outcomes of interest may be broader than those captured by standard  
1072 utility measures, and preference-weighted measures could be applied instead. For  
1073 example, specific quality-of-life measures that can be used for the analysis of  
1074 interventions for social care are recognised, such as the Adult Social Care Outcomes  
1075 Toolkit (ASCOT) set of instruments used by the Department of Health and Social Care in the  
1076 Adult Social Care Outcomes Framework indicator on social care-related quality of life.

1077

1078 7.4.2.3 Resource use and costs

1079 Resource use and costs used within the economic model should reflect the perspective of  
1080 the analysis and all relevant costs should be included. Data may be from several different  
1081 sources and choices should be justified within the EAR. There should be a preference for  
1082 recent cost data, from countries most applicable to the UK. If required, costs used in the  
1083 model should be converted to GBP and inflated to the current cost year.

1084 Resource use data may be available within studies reported in the effectiveness section of  
1085 the EAR. Alternatively, data may be available in published economic analyses. Information  
1086 on resource impact costings can be found in NICE's process guide on resource impact  
1087 assessment. Some information about public services may be better obtained from  
1088 national statistics or databases, rather than from published studies. Philips et al. (2004)  
1089 provide a useful guide to searching for data for use in economic models. It may be  
1090 necessary to elicit assumptions from experts if no data are available.

1091 There are several resources that could be used for specific costs. Two key sources of  
1092 national unit costs are the Personal Social Services Research Unit (PSSRU), which reports  
1093 unit costs of health and social care, and NHS Reference Costs, which reports the average  
1094 costs for procedures and services provided to patients. Public list prices can be used to  
1095 source costs of specific devices where available. Where this is not possible, costs of  
1096 devices can usually be obtained from the manufacturer. Costs of specific medicines can  
1097 be sourced from the British National Formulary (BNF) or the Monthly Index of Medical  
1098 Specialities (MIMS) or the electronic market information tool (eMIT).

1099



1100 7.4.3 Interpreting results

1101 The results of the analysis should be presented in a transparent way. Key results of a cost-  
1102 utility analysis should be presented in a table outlining the total costs, total life years, and  
1103 total QALYs for each intervention arm, in addition to incremental results between model  
1104 arms, including the corresponding incremental cost-effectiveness ratio (ICER).

1105 The results of the analysis vary depending on the type of analysis that has been conducted.  
1106 However, it will typically include an estimation of total costs and effectiveness for the  
1107 intervention and comparators over the modelled time horizon. If a cost effectiveness  
1108 analysis has been conducted, then the results will also include an estimation of the ICER  
1109 expressed as a 'cost per unit of effectiveness'. If a cost-utility analysis has been conducted,  
1110 then this ICER will be expressed as a cost per QALY. In such cases, the ICER is compared  
1111 against our chosen cost-effectiveness threshold of £20,000 per QALY. An intervention  
1112 which provides an additional QALY for less than £20,000 would therefore be considered  
1113 cost effective.

1114

1115 7.4.4 Uncertainty and sensitivity analysis

1116 The results of any modelled analysis will be subject to uncertainty. We conduct sensitivity  
1117 and scenario analyses to explore uncertainty and measure the impact that uncertainty  
1118 could have on modelled results.

1119

1120 7.4.4.1 Deterministic sensitivity analysis

1121 We use deterministic sensitivity analysis to explore the uncertainty around an individual  
1122 input parameter in the model. This involves independently varying an input parameter to  
1123 assess the impact that the change has on the modelled results.

1124

1125 7.4.4.2 Probabilistic sensitivity analysis

1126 We use probabilistic sensitivity analysis to explore the combined uncertainty around  
1127 model inputs. In this analysis, the mean values used in the base case are replaced with  
1128 values drawn from distributions around the mean values. Changes to inputs are made  
1129 simultaneously with an entirely new set of inputs for each model run. This process is  
1130 repeated until modelled results converge and average results of the analysis are presented.

1131

1132 7.4.4.3 Scenario analysis

1133 Scenario analyses are useful for testing assumptions made in the model and can  
1134 determine whether using alternative assumptions would impact the conclusions of the  
1135 analysis. Common scenario analyses include subgroup analysis to explore whether the  
1136 intervention may be more cost effective in a particular subgroup of the population (such  
1137 as a 'high risk' subgroup).

1138



1139 **7.5 PPI**

1140 For each EAR, PPI mechanisms will be determined in line with the process outlined in  
1141 Section 7.1.3. This section outlines what is involved for different PPI mechanisms, and how  
1142 this information is incorporated into the EAR.

1143 PPI mechanisms include:

- 1144 • patient and carer submissions (via a patient or carer organisation)
- 1145 • questionnaires or surveys (via a patient or carer organisation)
- 1146 • focus groups (via a patient or carer organisation)
- 1147 • PPI literature searches

1148 Any patient literature identified through the clinical evidence searches, such as evidence  
1149 on patient experiences and perspectives, is also included in the EAR for all topics.

1150

1151 7.5.1 Engagement with patient and carer organisations

1152 The PPI evidence represents the views, opinions, and experiences of organisations and  
1153 their networks of patients and users of social care, and therefore does not represent the  
1154 view or position of HTW. Any form of PPI obtained through engagement with an  
1155 organisation, regardless of additional support from HTW, must be approved by the  
1156 organisation involved before it can be included in the EAR. By taking this approach, HTW's  
1157 PPI is subject to the UK National Standards for Public Involvement and the standards set  
1158 out by Participation Cymru.

1159 As rapid HTA is not primary research, PPI contributions to the EAR are made in the name of  
1160 the organisation representing the views, interests, and rights of patients, their families,  
1161 carers, or individuals. Relevant organisations are identified through recommendation from  
1162 the PPISG or by searches based on HTW's standardised list of sources, which includes  
1163 relevant reviews undertaken by other HTA organisations.

1164 Once identified, organisations are approached with a formal request to take part in an  
1165 appraisal. Organisations must complete a DoI form, but they do not need to complete a  
1166 confidentiality agreement unless they see a draft of the EAR.

1167 HTW works with the organisation to get the most appropriate form of engagement  
1168 wherever possible. This may include taking a more flexible approach to evidence collection  
1169 and providing additional support to the organisation for the data collection and report  
1170 writing.

1171 Each EAR may involve engagement with a number of different patient, service-user, and  
1172 carer organisations, and their preferred method of engagement may vary.

1173

1174 7.5.1.1 Patient and carer submissions

1175 HTW's Patient and Carer Submission template is the most frequently used form of  
1176 participation we offer. It includes a mix of standard and tailored questions for the topic  
1177 under appraisal. These submissions are completed by a representative of the patient,  
1178 service-user, or carer organisation.



1179 A summary of the submissions, written by the PPI Manager, is included in the main body  
1180 of the EAR. The summary includes points from each submission that are relevant to:

- 1181 • the health condition or need for care
- 1182 • the health or social care technology or model of care and support, and
- 1183 • patient-reported outcomes and any other points of relevance.

1184 The full submission from the organisation is also included in the appendices of the EAR.

1185

#### 1186 7.5.1.2 Direct patient evidence

1187 A patient, service-user, or carer organisation may feel that they wish to collect data directly  
1188 from their own groups of patients, users of social care, and informal carers for a  
1189 submission. This may take the form of questionnaires, surveys, or focus groups. In most  
1190 cases, these submissions are coordinated by the patient, service-user, or carer  
1191 organisation, rather than HTW. However, HTW often work with the organisation to co-  
1192 produce the questions that people are asked. Any direct evidence from patients or users of  
1193 social care is anonymised and summarised as a report by the patient, service-user, or carer  
1194 organisation. Reports will contain a summary of methods, the results of the engagement  
1195 activity, and conclusions or key messages. These reports will be included in full in the EAR.

1196

#### 1197 7.5.2 PPI literature reviews

1198 There are two methods for summarising existing PPI literature. The first is an ‘easy access’  
1199 review, where an existing, recent HTA from another agency has been identified in the  
1200 clinical evidence review and includes PPI evidence. The patient evidence or PPI from the  
1201 previous HTA is summarised in the EAR and adapted where necessary. For example, where  
1202 the previous HTA is on a wider population or different intervention, we would focus on the  
1203 aspects specific to our own appraisal. This eliminates the need to perform a literature  
1204 search for relevant PPI articles.

1205 The second method is to perform a search for relevant PPI-related articles. Search  
1206 strategies are determined and reflect the basic structure of the patient and carer  
1207 submission, in that information can be gathered on:

- 1208 • the health condition or need for care
- 1209 • the health or social care technology or model of care and support
- 1210 • patient outcomes, patient decision making and patient-related behaviours that  
1211 may impact the success of the intervention.

1212 A PPI literature search considers the outcomes of the EAR and how it can add to and  
1213 support the effectiveness evidence. It considers broader perspectives and experiences that  
1214 would not be included in the effectiveness evidence, but would still add value to the  
1215 appraisal. These can include:

- 1216 • What it is like to live with the health condition or need for care
- 1217 • What the current barriers are for people who try to access care
- 1218 • What the current situation is for people with these needs in Wales
- 1219 • How patients or users of social care make decisions about their care and what  
1220 influences them (for example, would they be put off by social stigma, would they





1221 have to travel far, is there a type of intervention that they would consider  
1222 unfeasible)

- 1223 • How attitudes and behaviours impact how successful care might be.

1224 It may be appropriate to broaden the scope of the PPI search to include different  
1225 populations if the technology or model of care and support is the same and the experiences  
1226 of these people would be relevant. For example, if the population under appraisal is people  
1227 with gestational diabetes, and patient evidence is available for people with type 1 diabetes,  
1228 but all variables around the use of the device remain the same.

1229 The selection criteria for PPI evidence are different to the criteria used to identify  
1230 effectiveness and cost-effectiveness evidence. Articles are excluded if they are not  
1231 qualitative in nature (for example, clinical patient-related outcomes, such as satisfaction  
1232 rates, adherence rates, scales, and statistical analyses) and if they do not represent the  
1233 view of patients, users of social care, and informal carers (for example, the views of  
1234 healthcare professionals or other stakeholders). The amount of relevant PPI evidence is  
1235 often limited; therefore, we do not apply search date limitations to PPI literature searches,  
1236 and we do not limit by study size or relevancy to Welsh populations. Any relevant evidence  
1237 identified in the PPI literature searches is shared with the Researchers in the project team  
1238 to ensure there is no cross over or duplication with the effectiveness evidence.

1239 Once selected, the PPI evidence is summarised narratively and included in the EAR.

1240

## 1241 **7.6 Additional considerations**

1242 Inclusion of additional considerations that provide contextual information alongside other  
1243 parts of the EAR may be appropriate. Additional considerations may relate to service  
1244 structure and delivery, training requirements, workforce, equity, environmental  
1245 sustainability, or other issues relevant to provision of health and social care in Wales.

1246 Additional considerations will be taken into account where they are raised by the topic  
1247 proposer, by the HTW Assessment Group, or during expert review, or where they are  
1248 identified in the literature. Considerations identified during these stages of our process  
1249 will be included in the EAR where they are judged to be relevant for decision making and  
1250 sufficient supporting evidence has been identified.

1251 Additional considerations may also arise during HTW Appraisal Panel discussions and  
1252 have an impact on decision making. These will be reported in the guidance document  
1253 within the Appraisal Panel considerations section.

1254

## 1255 **7.7 Quality assurance, oversight, and external review**

1256 During the appraisal process, an EAR undergoes several forms of quality assurance and  
1257 review.

1258

### 1259 7.7.1 Quality assurance

1260 Each appraisal is overseen by a Senior Health Economist and Senior Health Services  
1261 Researcher. These staff members are responsible for internal quality assurance, which  
1262 includes:



- 1263 • checking the overall structure of the report is logical and complete
- 1264 • checking the effectiveness and cost-effectiveness sections use appropriate
- 1265 methods and document these clearly
- 1266 • checking that all key information needed to interpret these sections is present
- 1267 • checking that data have been reported appropriately and accurately
- 1268 • checking that appropriate conclusions have been drawn.

1269 As well as carrying out a formal check of these issues, those responsible for quality  
1270 assurance provide ongoing guidance and oversight to other members of the project team  
1271 during drafting of the report.

1272 In addition, information specialists quality assure the references of each EAR, to ensure that  
1273 each citation is correct and follows HTW's citation style.

1274

### 1275 7.7.2. Review by the HTW Assessment Group

1276 As noted in Section 3.2.1.2 it is the responsibility of the Assessment Group to review and  
1277 quality assure the EARs on behalf of the HTW Appraisal Panel, as well as provide assurance  
1278 on methodological and scientific rigour.

1279 Each EAR is seen by the Assessment Group on at least three occasions:

- 1280 • Prior to expert review: A draft report is prepared and discussed with the  
1281 Assessment Group; discussion focusses on any uncertainties and how to address  
1282 them, any suggestions for other changes, nominations for subject experts to  
1283 review the EAR, and potential questions for experts.
- 1284 • Post-expert review: Once all expert comments are received, proposed changes are  
1285 submitted to the Assessment Group for consideration, and agreement is reached  
1286 on updates required to the EAR.
- 1287 • Final EAR: Prior to submission to the Appraisal Panel, the Assessment Group  
1288 receives a final copy of the EAR, following incorporation of changes agreed and the  
1289 updated literature review, for sign off.

1290

### 1291 7.7.3 External expert review

1292 As part of our appraisal process, we invite experts in the field of a particular topic to review  
1293 our work. We ask reviewers to critically read the EAR and provide comment, either on  
1294 specific issues or uncertainties that HTW staff need help clarifying, or the general content  
1295 of the report and its robustness. We provide a response document with some key questions  
1296 to assist with this. Participants in the process are selected as outlined in Section 3.

1297 A list of experts who respond to external review will be listed in the EAR appendices. In  
1298 addition, stakeholders who were asked to comment but did not return a response, will also  
1299 be included in the appendices without personal information.

1300 Contributions from expert reviewers will be considered by the HTW Assessment Group and  
1301 the HTW Appraisal Panel. Expert reviewers will have no role in authorship or editorial  
1302 control; HTW reserves the right to make significant changes to the final publication  
1303 following consideration of comments received. The views expressed in the final publication  
1304 will be those of HTW.



1305 Where feedback from experts or the Assessment Group or other circumstances result in  
1306 major revisions or delays to the EAR, more than one round of expert review may be  
1307 undertaken. This will be agreed with the Assessment Group where necessary and the  
1308 original experts will be invited to review the updated EAR, along with any additional experts  
1309 identified in the interim.

1310

## 1311 **7.8 Finalising the EAR**

### 1312 7.8.1 Update literature review

1313 Researching and writing an EAR typically takes three to six months, so to ensure the  
1314 evidence is as current as possible, an update to the literature search is carried out,  
1315 approximately one to two months prior to publication. The aim of this is to identify any  
1316 evidence published since the original search that could impact on the findings of the EAR.

1317 Any evidence found by the update search will be considered using the same inclusion and  
1318 exclusion criteria used throughout the appraisal. Any new sources of evidence will be  
1319 incorporated into the EAR and their implications for the overall findings of the EAR  
1320 considered, initially by the HTW project team. If there are concerns that newly identified  
1321 sources of evidence are critical to decision making, or independent input is needed into  
1322 their relevance or implications on decision making, the updated EAR will undergo further  
1323 discussion with the Assessment Group and, in exceptional circumstances, may be re-  
1324 reviewed by subject experts before proceeding to the Appraisal Panel.

1325

### 1326 7.8.2 Agreement to progress to guidance

1327 On their final review of the EAR, the Assessment Group will determine that they are  
1328 satisfied that all expert review comments and other outstanding recommendations of the  
1329 Assessment Group have been or can be addressed prior to the Appraisal Panel.

1330 In exceptional cases, the Assessment Group will decide that it is inappropriate to progress  
1331 to the Appraisal Panel or to produce guidance. In these cases, a summary is produced along  
1332 with the EAR. This does not contain any guidance recommendations, and explains the  
1333 rationale for not producing guidance. The summary of the evidence is written by the HTW  
1334 project team and signed off by the Assessment Group prior to publication on our website.

1335

## 1336 **8. Production of HTW guidance**

1337 HTW guidance outlines the view of HTW on the effectiveness, safety, and cost effectiveness  
1338 of the technology or model of care and support being appraised, within the context of the  
1339 Welsh health and social care system.

1340 HTW guidance has a status of “adopt or justify” and there is an expectation from Welsh  
1341 Government that our guidance is considered by relevant commissioners. However, HTW  
1342 guidance is not mandatory. There may be instances where there are reasons for not  
1343 following recommendations and it is acknowledged that HTW guidance constitutes only  
1344 one of the sources needed for decision making and planning in NHS and social care  
1345 services in Wales. HTW guidance does not override the responsibility of health and social  
1346 care professionals to consider the circumstances of individuals in their care and exercise



1347 appropriate judgement in consultation with the person being cared for and/or their  
1348 guardian or carer.

1349

### 1350 **8.1 The HTW Appraisal Panel**

1351 Once an EAR is completed and the Assessment Group have agreed that it is appropriate for  
1352 HTW guidance on the topic to be produced, it will be considered at an Appraisal Panel  
1353 meeting. It is at this meeting that HTW guidance is drafted, deliberated, and agreed.

1354 The Appraisal Panel considers the EAR produced by HTW, as well as views and comments  
1355 provided by clinical and PPI experts during the meeting, to ensure that the implications for  
1356 NHS Wales and the social care sector in Wales are given due consideration.

1357 Key factors considered by the Appraisal Panel when drafting guidance, include:

- 1358 • Evidence of effectiveness: the number of studies and the number of patients  
1359 studied to address the question of interest. Is evidence available that allows direct  
1360 comparison of the technology or model of care and support with current  
1361 alternatives, and is evidence available for all relevant outcomes?
- 1362 • Certainty of the evidence: the extent to which studies are protected from potential  
1363 biases that may impact upon the relationship between an intervention and an  
1364 outcome. A high-quality study is more likely to protect the integrity of this  
1365 relationship.
- 1366 • Consistency of the evidence: the degree to which different study results are in  
1367 agreement for the same outcome.
- 1368 • Applicability and generalisability of the evidence: the degree to which populations  
1369 and pathways in studies reflect the Welsh context and practice.

1370

#### 1371 8.1.2 Meeting attendees

1372 Membership of the HTW Appraisal Panel is outlined in Section 3. In addition to Appraisal  
1373 Panel members, additional guests will be invited to provide members with further detail  
1374 on the topic. This includes:

- 1375 • Patient and carer organisation representatives
- 1376 • Subject matter experts

1377 The HTW Appraisal Panel meeting is open to public observers (except for confidential  
1378 discussions). Members of the public who wish to observe the meeting must sign up in  
1379 advance via our website.

1380

#### 1381 8.1.3 Format of meetings

1382 Appraisal Panel meetings are scheduled virtually each month. The Appraisal Panel will  
1383 consider up to two topics per meeting.

1384 For each topic, the meeting commences with an introduction to the topic and a summary  
1385 of the evidence presented in the EAR, including PPI considerations. Members will then  
1386 undertake a question-and-answer session with the HTW project team and invited experts  
1387 and PPI contributors.



1388 This will then be followed by a closed panel discussion during which time the guidance will  
1389 be formulated.

1390

#### 1391 8.1.4 Potential outcomes

1392 HTW drafts guidance considering the specific circumstances of the technology or model  
1393 of care and support, and the population being appraised. We do not use set wording and  
1394 formatting for our guidance but, in general terms, there are five main types of guidance  
1395 outcome:

- 1396 • Evidence supports routine adoption: The evidence suggests that the technology or  
1397 model of care and support is effective and cost effective for the full population  
1398 being considered in the guidance. Therefore, it is recommended that the  
1399 technology or model of care and support is routinely adopted.
- 1400 • Evidence supports partial adoption: The evidence suggests that the technology or  
1401 model of care and support is effective and cost effective for a subgroup or subset  
1402 of the population being considered in the guidance. Therefore, it is recommended  
1403 that the technology or model of care and support is selectively adopted in the  
1404 indicated population.
- 1405 • Evidence partially supports adoption: There is some evidence to suggest that the  
1406 technology or model of care and support is effective and cost effective but there is  
1407 uncertainty around the evidence base. For example, there may be evidence to  
1408 suggest that the technology or model of care and support is effective but there  
1409 may be uncertainty around cost effectiveness.
- 1410 • Insufficient evidence to support adoption: There is not enough evidence to  
1411 determine whether the technology or model of care and support is effective and  
1412 cost effective. In some cases, this may reflect a general paucity of evidence,  
1413 whereas in other cases it may reflect uncertainty in the outcomes from studies  
1414 identified in the evidence base.
- 1415 • Evidence does not support adoption: The evidence identified suggests that the  
1416 technology or model of care and support is not effective and/or cost effective.  
1417 Therefore, it is recommended that the technology or model of care and support is  
1418 not adopted.

1419

#### 1420 **8.2 Drafting the guidance**

1421 Following the Appraisal Panel meeting, the first full draft of the HTW guidance document  
1422 is prepared by the HTW project team in line with the discussions in the Appraisal Panel  
1423 meeting.

1424 This document includes:

- 1425 • The HTW guidance recommendation
- 1426 • Why the topic was considered for appraisal
- 1427 • A summary of the evidence from the EAR
- 1428 • A summary of the Appraisal Panel's considerations
- 1429 • The responsibilities for consideration of the guidance



1430 The document will also outline any suggestions or considerations for further research put  
1431 forward by the Appraisal Panel.

1432

### 1433 **8.3 Guidance sign off**

1434 The draft guidance is emailed to the HTW Chair for initial review.

1435 Once the HTW Chair has reviewed the HTW guidance document, it is circulated to all  
1436 Appraisal Panel members for further comment or clarification. Any revisions are  
1437 incorporated into a final draft by the HTW project team and signed off by the HTW Chair.

1438

### 1439 **8.4 Publication and dissemination of guidance**

1440 The following are available on the HTW website when guidance is published:

- 1441 • The outcome of the appraisal: this summarises key findings of the HTW guidance  
1442 in terms of whether a technology or model of care and support should be adopted  
1443 and the rationale for this.
- 1444 • Why the topic was appraised: this summarises the health problem or need for  
1445 care, how the technology or model of care and support addresses it, and if  
1446 relevant, why guidance was needed and who requested it.

1447 A plain language summary is also provided. This combines the information in the above  
1448 two sections and is published alongside them.

1449 The following documentation is published which expands on the information above:

- 1450 • Guidance
- 1451 • EAR

1452 The outcomes of the appraisal, why the topic was appraised, a plain language summary  
1453 and the guidance document are published in Welsh and English. Other documents are  
1454 published in English but available in Welsh upon request. Where necessary, any  
1455 confidential information will be redacted from the EAR or other supporting documents  
1456 before publication.

1457 Once our guidance is published, we disseminate it via social media and publication of a  
1458 news story on our website. A guidance alert is sent to contacts who have subscribed to  
1459 receive our guidance alerts. We also contact any organisations who our guidance may  
1460 impact upon (such as health boards, local authorities, trade or industry bodies, third  
1461 sector organisations, and professional organisations).

1462

### 1463 **8.5. Challenges to guidance**

1464 The methodology adopted in the development of HTW guidance includes consulting with  
1465 relevant experts and stakeholders throughout the process, with the aim of minimising  
1466 disagreements on the content of the final published HTW guidance. However, it is  
1467 recognised that there may be occasions when challenges will arise. An individual or  
1468 organisation may consider that HTW has:



- 1469
- 1470
- 1471
- 1472
- Misinterpreted the evidence contained within the EAR on which the HTW guidance is based;
  - Given insufficient attention to, or misused, relevant contextual material; or
  - Deviated significantly from due HTW process when preparing the advice.

1473 If so, the organisation or individual should contact HTW in writing  
1474 ([healthtechnology@wales.nhs.uk](mailto:healthtechnology@wales.nhs.uk)), setting out their concerns. These concerns will be  
1475 considered by the HTW Chair, HTW's senior team, and the Chair of the HTW Assessment  
1476 Group.

1477 If concerns cannot be resolved informally by discussion, they will be considered by the HTW  
1478 Assessment Group. As a minimum, the Assessment Group will review the original guidance  
1479 and the accompanying EAR.

1480 If concerns remain unresolved, an organisation or individual has the option of requesting  
1481 a formal review, through the constitution of an Independent Review Panel (IRP). A request  
1482 to set up an IRP must be made in writing to the HTW Programme Office within three months  
1483 of the publication of the HTW guidance.

1484 The decision to convene an IRP will be considered by the Director of HTW and HTW Chair. If  
1485 the decision is not to proceed with an IRP, the individual or organisation that requested  
1486 the review will be informed within three months. They will be given the reasons on which  
1487 the decision was based.

1488 If the decision is to convene an IRP, this will be held within three months of receiving the  
1489 request. The IRP shall comprise a minimum of four members:

- 1490
- 1491
- 1492
- 1493
- 1494
- 1495
- An independent Chair for the IRP.
  - Two or more members, appointed by the independent IRP Chair, who are recognised experts in the relevant scientific field, and who have not been involved in the HTW EAR or guidance production.
  - One or more independent member(s), for example, a public or industry partner, or former member(s) of the Appraisal Panel.

1496 Dols will be recorded for all IRP participants.

1497 A note will be made on the HTW website that the HTW guidance is under review.

1498 The IRP will review the original guidance, the expert review comments received and  
1499 response of HTW to these comments, the accompanying EAR, the original topic referral  
1500 form, and the papers of the Assessment Group and Appraisal Panel meetings at which the  
1501 topic was discussed. The IRP may also consider evidence from the individual or  
1502 organisation who is challenging the HTW guidance, but this evidence should remain  
1503 relevant to the appraisal review question, and cannot include any evidence published since  
1504 the original appraisal concluded. Where evidence is not considered relevant, HTW may  
1505 choose to exclude it, with justification for doing so.

1506 IRP members will vote on the decision to amend the guidance or not. Each member will  
1507 have one vote and the Chair will be given a casting vote. Should support and advice be  
1508 required then this will be provided by the HTW Programme Office.

1509 The person or organisation submitting the review request will be informed in writing of the  
1510 results of the review within two weeks of the date of the IRP meeting. If the IRP believe that  
1511 due process has been followed and that evidence and contextual information has been



1512 appropriately interpreted, then no action will be taken. If the IRP believe that amendments  
1513 are required, their conclusions and recommendations will be reviewed at a subsequent  
1514 HTW Appraisal Panel meeting and revised HTW guidance issued.

1515

## 1516 **9. Impact and adoption of guidance**

1517 HTW monitors the impact of our appraisals, guidance, and wider work on improving the  
1518 health, wellbeing, and value for people in Wales. To track and report on the impact of our  
1519 work, we use a contribution analysis-based approach (developed by the external company  
1520 Matter of Focus).

1521 Contribution analysis is a theory of change approach that acknowledges that change and  
1522 outcomes are not driven by direct cause and effect. This works well when you are evaluating  
1523 actions within a complex system, like the Welsh health and social care ecosystem, where  
1524 there are many different factors that influence the outcomes. Evidence of HTW's impact is  
1525 captured via multiple quantitative and qualitative data sources.

1526 We also monitor the uptake of our guidance, via the annual adoption audit. Through the  
1527 adoption audit, HTW assesses and reports on the extent to which relevant commissioners  
1528 have considered guidance, made steps towards adoption, and justified non-adoption. For  
1529 details on our adoption audit methodology, please see our annual adoption audit reports.

1530

## 1531 **10. Review and re-assessment**

1532 HTW aims to ensure our guidance remains current and relevant after publication. We will  
1533 consider guidance for re-assessment either at the request of stakeholders, or where our  
1534 own intelligence indicates the guidance may require updating. Such circumstances could  
1535 include:

- 1536 • Substantial new evidence that is likely to alter conclusions on the effectiveness or  
1537 cost effectiveness of the appraised technology or model of care and support
- 1538 • A shift in practice which means the appraised technology or model of care and  
1539 support's place in the care pathway needs to be reviewed
- 1540 • Changes to standard care that could alter the effectiveness or cost effectiveness  
1541 of the appraised technology or model of care and support

1542 When re-assessment is considered or requested, HTW staff will contact stakeholders to  
1543 ascertain whether the research question is still relevant and if there have been any  
1544 developments to the evidence base. These stakeholders include:

- 1545 • The original appraisal stakeholders
- 1546 • Anyone relevant who has accessed the original HTW guidance on the HTW website,  
1547 and given their permission to be contacted
- 1548 • Any new patient or public organisation contacts suggested by the PPISG
- 1549 • Welsh NICE Health Network
- 1550 • HTW Stakeholder Forum

1551 Stakeholders will be updated by email on the decision of whether to progress with a  
1552 reassessment on the topic, following consideration by the Assessment Group.





1553 Where necessary, HTW staff also undertake a high-level literature search to provide an  
1554 update on the available evidence on a topic.

1555 Stakeholder feedback and any newly identified evidence are considered by the Assessment  
1556 Group, who will recommend whether guidance should be updated. When the decision is to  
1557 update guidance, the topic will follow the standard HTW appraisal process described  
1558 earlier in this document. Existing appraisal documentation such as the EAR will be re-used  
1559 and updated as necessary.

## 1560 **11. Abbreviations**

1561 AP Appraisal Panel

1562 AG Assessment Group

1563 ASCOT Adult Social Care Outcome Toolkit

1564 AWMSG All Wales Medicines Strategy Group

1565 BNF British National Formulary

1566 DoI declaration of interest

1567 EAR Evidence Appraisal Report

1568 eMIT electronic market information tool

1569 EQ-5D EuroQol Five-Dimensions

1570 HTA health technology assessment

1571 HTW Health Technology Wales

1572 ICER incremental cost-effectiveness ratio

1573 IRP Independent Review Panel

1574 MIMS Monthly Index of Medical Specialities

1575 ONS Office for National Statistics

1576 PPI patient and public involvement

1577 PPISG Patient and Public Involvement Standing Group

1578 PSSRU Personal Social Services Research Unit

1579 QALY quality-adjusted life year

1580 RCT randomised controlled trial

1581 SF-36 36-Item Short Form Health Survey

1582 TER Topic Exploration Report

1583 [DOCUMENT HISTORY]

1584 [ACKNOWLEDGEMENTS]

1585 [REFERENCES]

1586 [GLOSSARY TO BE ADDED]



1587 [ANY OTHER APPENDICES]